Watch List for Traders: Permian Basin Royalty Trust (NYSE:PBT), ConocoPhillips (NYSE:COP), Dipexium Pharmaceuticals (NASDAQ:DPRX), Gold Standard Ventures Corp (NYSEMKT:GSV)


Vapor Corp. (NASDAQ:VPCO) shares decreased -62.50% in last trading session and ended the day at $0.00. VPCO Gross Margin is -2.20% and its has a return on assets of -83.00%. Vapor Corp. (NASDAQ:VPCO) quarterly performance is -99.81%.

Vapor Corp. (NASDAQ:VPCO) announced the results of its Special Meeting of Stockholders scheduled for Thursday, January 28, 2016 and adjourned to today. At the Special Meeting, Vapor’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio between 1-for-10 and 1-for-70, such ratio to be determined by the board of directors of the Company, to reduce the par value of the Company’s common stock from $0.001 to $0.0001 (the “Reverse Stock Split”), and to increase the number of authorized shares of the Company’s common stock from 500,000,000 shares, par value $0.001, to 5,000,000,000, par value $0.0001 (the “Authorized Share Increase”).

Permian Basin Royalty Trust (NYSE:PBT) ended the last trading day at $5.23. Company weekly volatility is calculated as 4.80% and price to cash ratio as 174.12. Permian Basin Royalty Trust (NYSE:PBT) showed a weekly performance of -2.97%.

Permian Basin Royalty Trust (NYSE:PBT) declared a cash distribution to the holders of its units of beneficial interest of $0.014734 per unit, payable on February 12, 2016, to unit holders of record on January 29, 2016.

ConocoPhillips (NYSE:COP) shares fell -1.42% in last trading session and ended the day at $31.88. COP Gross Margin is 33.80% and its has a return on assets of -0.90%. ConocoPhillips (NYSE:COP) quarterly performance is -41.67%.

ConocoPhillips (NYSE:COP) said it is lowering its dividend to 25 cents per share from 74 cents per share. The dividend is payable on March 1 to shareholders of record on Feb. 16. The company also reduced its 2016 capital expenditures outlook and operating cost guidance.

Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) shares decreased -0.64% in last trading session and ended the day at $7.73. DPRX has a return on assets of -51.20%. Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) quarterly performance is -35.15%.

On 4 February, Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) announced its OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials (180 patients per clinical trial) being conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers.

Gold Standard Ventures Corp (NYSEMKT:GSV) caters to the Basic Materials space. Its weekly performance is 8.31%. On the last day of trading company shares ended up at $0.80. Gold Standard Ventures Corp (NYSEMKT:GSV) distance from 50-day simple moving average (SMA50) is 25.98%.

On 9 February, Gold Standard Ventures Corp (NYSEMKT:GSV) report that it closed its previously announced private placement financing (the “Financing”) with Goldcorp Inc. (TSX:G)(GG) (“Goldcorp”) for 16,100,000 common shares of Gold Standard (the “Purchased Shares”) at a price of C$1.00 per share for gross proceeds of C$16,100,000. Goldcorp now owns approximately 9.9% of the Company’s issued and outstanding shares on an undiluted basis.


Leave a Reply

Your email address will not be published. Required fields are marked *